Skip to content

[Simagery] Targeting repetitive intrusive suicidal images and thoughts: towards a new suicide prevention strategy

Feasibility and safety aspects surrounding the add-on Eye Movement Dual Task intervention: a pilot study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON27900
Enrollment
6
Registered
2018-05-04
Start date
2017-11-17
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Suicidal, intrusions, mental problems, depression,

Interventions

EMDT add-on treatment The treatment will be an add-on module that addresses intrusive suicidal images and can be added to regular treatment. It will consist of max. six sessions each of approximately

Sponsors

Vrije Universiteit Amsterdam
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: a. Have a minimum age of 18 years b. Score >20 on the Beck Depression Inventory c. Have suicidal ideation: score >20 on Suicidal Ideation Attributes Scale (SIDAS) d. Currently receiving treatment (Care-as-usual) at GGZ InGeest Amsterdam e. Adequate proficiency in the Dutch language f. Have suicidal intrusions (as measured through the Intrusion Interview) that are experienced as a burden

Exclusion criteria

Exclusion criteria: a. DSM-IV Psychotic disorder diagnosis b. DSM-IV Depression with psychotic features diagnosis c. DSM-IV Bipolar disorder diagnosis d. High dropout risk (i.e. poor response rate when trying to get in contact with potential participant)

Design outcomes

Primary

MeasureTime frame
Feasibility (measured by i.e. treatment adherence and data collection using online questionnaires)

Secondary

MeasureTime frame
Suicidal ideation (BSSI, SIDAS), depressive symptoms (BDI-II), suicidal intrusions (SINAS), Psychological distress (BSI)

Contacts

Public ContactJaël Bentum, van

Department of Clinical Psychology, Vrije Universiteit Amsterdam

j.s.van.bentum@vu.nl+31 20 598 6615

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)